The 2021 APBI Code was approved by ABPI members at a special General Meeting on Tuesday 12 January 2021. It will come into operation on 1 July 2021.
Click for further information - here
The Prescription Medicines Code of Practice Authority
The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI. It was established by the ABPI on 1 January 1993.
The Authority is responsible for the provision of advice, guidance and training on the Code as well as for the complaints procedure. It is also responsible for arranging for conciliation between companies when requested to do so and for arranging for the scrutiny of advertising and meetings on a regular basis.
The PMCPA was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry, independently of the ABPI.
The aim of the Code is to ensure that the promotion of medicines by the pharmaceutical industry is carried out within a robust framework, to support high quality patient care.
Code of Practice Seminars
- dates under review. Due to government guidance on COVID-19 the PMCPA has cancelled the Seminar previously scheduled for June 2020 and further dates are subject to change.
ABPI Examination for Medical Representatives
- postponed due to COVID-19. More information is available on the ABPI website, link below
To extend the time available to take the examination an application for an extension should be made on the form on this website, link below
The extension request should preferably be made by the company rather than the representative.
In house training
- under review due to COVID-19
- unavailable until after the next version of the ABPI Code has been agreed and implemented.
For more information see Training Opportunities.
Camurus, Accord, Swedish Orphan Biovitrum (Sobi), Strides Pharma, Boehringer Ingelheim, Vifor Pharma, GlaxoSmithKline and Sintetica named in advertisements for breaches of the ABPI Code
02 March 2021read more
The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 and changes to and impact on the 2019 ABPI Code of Practice for the Pharmaceutical Industry
16 February 2021read more